Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important means of treating a variety of hematologic disorders. With the progress of HSCT technology, especially the research on haploidentical transplantation (HID-HSCT), the range of donor choices for hematological patients has been expanded, and theoretically, the era of "everyone has a donor" has been reached, which has increased the chances for hematological patients to receive allo-HSCT . The efficacy of allo-HSCT has improved dramatically over the past decades, but post-transplant complications such as graft-versus-host disease (GvHD), infections, and disease recurrence may still lead to treatment failure. In order to improve the efficacy of allo-HSCT, in addition to the improvement of pretreatment regimen and post-transplant management, the selection of the best donor among the many alternatives (including sibling donors, parents, children, and collateral hematologic donors, etc.) is still the focus and difficulty of clinical decision-making. The existing studies on donor selection have suggested that the factors to be considered include the number of HLA mismatched sites, donor-recipient consanguinity, donor age and gender, donor-specific antibody (DSA), NK cell isotype reactivity, and clonal hematopoiesis of the donor . However, little is known about whether a donor with metabolic syndrome such as diabetes affects post-transplant survival in allo-HSCT recipients.

It has been shown that diabetes mellitus affects the number and function of hematopoietic and immune cells, and that these effects may be passed on to progeny blood cells through epigenetic mechanisms, with long-term effects on immune cell function in diabetic patients. We therefore hypothesized that the effects of abnormal glucose metabolism in donors on the hematopoietic system may affect hematopoiesis and immune reconstitution in transplant recipients through "metabolic memory". Therefore, the investigator conduct a multicenter retrospective study through multifactorial survival regression. It is expected to provide new theoretical support for optimizing donor selection for allo-HSCT.

• Non-relapse Mortality (NRM) [Срок оценки: One year since hematopoietic stem cell transplantation]
• Relapse-free Survival (RFS) [Срок оценки: One year since hematopoietic stem cell transplantation]
• Event-free Survival (EFS) [Срок оценки: One year since hematopoietic stem cell transplantation]
• Graft versus Host Disease (GvHD) incidence [Срок оценки: One year since hematopoietic stem cell transplantation]
• GvHD and Relapse-free Survival (GRFS) [Срок оценки: One year since hematopoietic stem cell transplantation]
• Cumulative Incidence Rate (CIR) [Срок оценки: One year since hematopoietic stem cell transplantation]
• Graft Time of Different Cell Subpopulation [Срок оценки: One year since hematopoietic stem cell transplantation]